HSP90AA1 and breast carcinoma: These results are consistent with clinical data previously reported by our group, suggesting that HSP90-overexpressing breast cancer clones may be more effectively eliminated by trastuzumab–docetaxel-based treatment, thereby translating into a higher proportion of pathologic complete response (pCR) [33].